RO7851624 for Multiple Myeloma That Has Returned or Stopped Responding to Treatment
Tests RO7851624 in adults with multiple myeloma who have few treatment options left.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Key facts
- Where
- Gangnam-Gu, South KoreaSee the site
- Phase
- Phase 1
Where in South Korea
- Samsung Medical CenterGangnam-Gu, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genentech, Inc.
- Trial code
- NCT07558915
- Record updated
- 9 November 2026
- Original description
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.Read full original descriptionShow less
An Open-Label, Multicenter, Phase Ia/b Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed/Refractory Multiple Myeloma
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.
Inclusion: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Life expectancy of at least 12 weeks; Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria; Measurable disease.
Exclusion: Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment; Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment; Prior allogeneic SCT; Prior solid organ transplantation.